ReviewGynecologic oncology reports2025
Obesity management in the setting of endometrial cancer and hyperplasia: A narrative review.
Review in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Management of Patients Diagnosed with Endometrial Hyperplasia: Comparison of Guidelines.Cancers · 2026Review
- The Association Between Cadmium Exposure and Endometrial Cancer Risk: Evidence from a Comprehensive Updated Meta-Analysis.Journal of clinical medicine · 2026Review
- Endometrial Hyperplasia: Current Insights into Epidemiology, Risk Factors, and Clinical Management.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a well-established risk factor for endometrial cancer, driven by chronic inflammation, insulin resistance, and excess estrogen. As the global obesity epidemic continues to worsen, effective weight management plays a crucial role in reducing both incidence and progression. Recent pharmacotherapy advancements, particularly GLP-1 receptor agonists, show promising weight loss effects by modulating appetite and metabolism. Preclinical studies suggest these agents may also influence cancer progression, though further clinical research is needed. Bariatric surgery remains the most effective long-term intervention for severe obesity, offering significant metabolic and hormonal benefits. Weight loss surgery is associated with reduced cancer risk and improvements in molecular markers, though findings on specific biomarkers remain inconsistent. This narrative review explores emerging weight loss interventions, focusing on novel pharmacologic agents and bariatric surgery, and their impact on endometrial cancer risk and outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.